Perspective Therapeutics Financials - Benzinga

Perspective Therapeutics Inc

CATXAMEX

Trade with Public

Trade with Public

$2.50

-0.02-0.79%

al cierre: Sep 25, 5:00 PM EST

$2.71

0.197.54%

Premercado: 8:36 AM EST

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

Perspective Therapeutics Financials

Perspective Therapeutics (CATX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Perspective Therapeutics Q2 EPS $(0.22) Beats $(0.26) Estimate, Sales $81.000K Miss $83.154K Estimate

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.26) by 15.38 percent. This is a 26.67 percent increase over losses of $(0.30) per

Benzinga Newsdesk

PRO
Perspective Therapeutics Q1 EPS $(0.25) Beats $(0.31) Estimate, Sales $76.000K Miss $136.917K Estimate

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.31) by 19.35 percent. This is unchanged from the same period last year. The company

Benzinga Newsdesk

Earnings Scheduled For May 11, 2026

Benzinga Insights

PRO
Perspective Therapeutics Q4 EPS $(0.51) Misses $(0.36) Estimate, Sales $43.000K Miss $215.615K Estimate.

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.36) by 42.06 percent. This is a 15 percent increase over losses of $(0.60) per share

Benzinga Newsdesk

Earnings Scheduled For March 16, 2026

Benzinga Insights

PRO
Perspective Therapeutics Q3 EPS $(0.35) Misses $(0.33) Estimate, Sales $209.000K Miss $223.833K Estimate

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.33) by 7.03 percent. This is a 66.67 percent decrease over losses of $(0.21) per

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved